A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Active, not recruiting · Phase 1 · NCT06220201
Conditions: Multiple Sclerosis, Myasthenia Gravis
At a glance
- Research payments reported, 2025
- $11,711
- U.S. investigators named
- 10
- Sites paid
- 10
- Planned or actual enrollment
- 120
About the trial
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (with Celgene Corporation)
- Tested
- CC-97540 (drug), Fludarabine (drug), Cyclophosphamide (drug)
- Dates
- Started 2024-03-28; completion 2027-07-15
- Results posted
- Not yet
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).
From ClinicalTrials.gov, last updated 2026-08-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $11,711 in research payments for this study in 2025 (10 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Khurram Bashir Neurology · Birmingham, AL
- Lazaros J. Lekakis, MD Hematology & Oncology · Miami, FL
- Susan E. Prockop, MD Pediatric Hematology & Oncology · Boston, MA
- Leslie P. Ranken, MD Rheumatology · Charlotte, NC
- Anca Askanase, MD Rheumatology · New York, NY
- Fred Lublin, M.D. Neurology · New York, NY
- Yuebing Li, MD Neurology · Cleveland, OH
- Aram Zabeti, M.D. Neurology · Cincinnati, OH
- Vijayshree Yadav, MD Neurology · Portland, OR
- Ahmed Z. Obeidat, M.D., P.H.D Neurology · Milwaukee, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Miami Hospital $1,608
- Ohsu Hospital and Clinics, OR $1,510
- Medical College of Wisconsin $1,412
- Icahn School of Medicine at Mount Sinai Department of Microbiology PAlese Laboratory $1,351
- Cleveland Clinic, OH $1,251
- University of Alabama Hospital, AL $1,233
- University of Cincinnati $1,062
- Atrium Health Integrative Medicine $855
- Columbia University Medical Center $735
- Boston Children's Hospital, MA $694
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.